A real-world study of karillicumab in the treatment of patients with advanced gastric cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000034921

Enrollment

Unknown

Registered

2020-07-24

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer

Interventions

trial group:Combined with apatinib mesylate ± chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Subjects aged over 18 years old; 2. The object of sex is not limited; 3. Patients with advanced gastric cancer confirmed by histopathology or cytology; 4. ECoG score: 0-2 points; 5. The patients with expected survival time >= 3 months; 6. The subjects volunteered to join the study, signed the informed consent form, had good compliance and cooperated with the follow-up; 7. The researchers believe that treatment can benefit.

Exclusion criteria

Exclusion criteria: 1. Patients who have been proved to be allergic to the test drug and / or its excipients; 2. Patients with immunodeficiency disease or history of organ transplantation; 3. Pregnant or lactating women; 4. According to the judgment of the researcher, the patients who are not suitable to be included in this study.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Secondary

Measure	Time frame
OS;ORR;DCR;AE;DOR;	—

Countries

China

Contacts

Public ContactGuoping Sun

The First Affiliated Hospital of Anhui Medical University

sungp123@126.com+86 551-62922114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026